Erasca Inc
ERAS12.290USD
+0.410+3.45%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
3.49BValor de mercado
PerdaP/L TTM
Mais detalhes de Erasca Inc Empresa
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Informações de Erasca Inc
Código da empresaERAS
Nome da EmpresaErasca Inc
Data de listagemJul 15, 2021
CEOLim (Jonathan E)
Número de funcionários103
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 15
Endereço3115 Merryfield Row
CidadeSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92121
Telefone18584656511
Sitehttps://www.erasca.com/
Código da empresaERAS
Data de listagemJul 15, 2021
CEOLim (Jonathan E)
Executivos da empresa Erasca Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
19.46M
--
Mr. Alexander W. (Alex) Casdin
Mr. Alexander W. (Alex) Casdin
Independent Director
Independent Director
667.72K
--
Dr. James Arthur Bristol
Dr. James Arthur Bristol
Lead Independent Director
Lead Independent Director
207.50K
--
Mr. Ebun S. Garner, J.D.
Mr. Ebun S. Garner, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
25.08K
--
Dr. David M. Chacko, M.D.
Dr. David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Julie Hambleton, M.D.
Dr. Julie Hambleton, M.D.
Independent Director
Independent Director
--
--
Dr. Valerie Harding-Start, Ph.D.
Dr. Valerie Harding-Start, Ph.D.
Independent Director
Independent Director
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Independent Director
Independent Director
--
--
Dr. Michael David Varney, Ph.D.
Dr. Michael David Varney, Ph.D.
Director, Chair of Research and Development and Scientific Advisory Board member
Director, Chair of Research and Development and Scientific Advisory Board member
--
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
19.46M
--
Mr. Alexander W. (Alex) Casdin
Mr. Alexander W. (Alex) Casdin
Independent Director
Independent Director
667.72K
--
Dr. James Arthur Bristol
Dr. James Arthur Bristol
Lead Independent Director
Lead Independent Director
207.50K
--
Mr. Ebun S. Garner, J.D.
Mr. Ebun S. Garner, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
25.08K
--
Dr. David M. Chacko, M.D.
Dr. David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Julie Hambleton, M.D.
Dr. Julie Hambleton, M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sex, 15 de ago
Atualizado em: sex, 15 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Frazier Life Sciences Management, L.P.
7.34%
T. Rowe Price Investment Management, Inc.
6.54%
Lim (Jonathan E)
6.28%
VR Adviser, LLC
5.77%
Paradigm BioCapital Advisors LP
4.90%
Outro
69.17%
Investidores
Investidores
Proporção
Frazier Life Sciences Management, L.P.
7.34%
T. Rowe Price Investment Management, Inc.
6.54%
Lim (Jonathan E)
6.28%
VR Adviser, LLC
5.77%
Paradigm BioCapital Advisors LP
4.90%
Outro
69.17%
Tipos de investidores
Investidores
Proporção
Investment Advisor
25.22%
Venture Capital
20.19%
Hedge Fund
15.24%
Private Equity
7.34%
Individual Investor
6.73%
Investment Advisor/Hedge Fund
5.48%
Corporation
3.98%
Research Firm
1.27%
Bank and Trust
0.09%
Outro
14.47%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
302
232.29M
89.71%
--
2025Q3
310
232.29M
93.65%
-60.69K
2025Q2
313
232.41M
93.79%
-6.69M
2025Q1
306
239.26M
97.34%
-36.46M
2024Q4
312
245.09M
99.26%
-1.10M
2024Q3
302
246.05M
87.29%
+28.86M
2024Q2
292
216.94M
64.16%
+84.80M
2024Q1
269
85.99M
67.39%
-16.11M
2023Q4
259
82.61M
63.62%
+857.42K
2023Q3
245
88.19M
71.92%
-4.14M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Frazier Life Sciences Management, L.P.
22.73M
8.01%
--
--
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
20.23M
7.13%
-100.25K
-0.49%
Sep 30, 2025
Lim (Jonathan E)
19.46M
6.86%
--
--
Apr 15, 2025
VR Adviser, LLC
17.86M
6.29%
--
--
Sep 30, 2025
Paradigm BioCapital Advisors LP
13.56M
4.78%
+1.65M
+13.88%
Sep 30, 2025
Logos Global Management LP
15.15M
5.34%
+150.00K
+1.00%
Sep 30, 2025
Suvretta Capital Management, LLC
14.50M
5.11%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
13.13M
4.63%
-195.87K
-1.47%
Sep 30, 2025
City Hill Ventures, LLC
12.90M
4.55%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
12.81M
4.52%
+116.23K
+0.92%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
1.07%
ALPS Medical Breakthroughs ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Micro-Cap ETF
0.08%
Invesco Nasdaq Biotechnology ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
iShares Biotechnology ETF
0.03%
ProShares UltraPro Russell2000
0.02%
iShares US Small-Cap Equity Factor ETF
0.02%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.07%
ALPS Medical Breakthroughs ETF
Proporção0.28%
ProShares Ultra Nasdaq Biotechnology
Proporção0.11%
iShares Micro-Cap ETF
Proporção0.08%
Invesco Nasdaq Biotechnology ETF
Proporção0.07%
Fidelity Enhanced Small Cap ETF
Proporção0.05%
iShares Russell 2000 Value ETF
Proporção0.04%
iShares Biotechnology ETF
Proporção0.03%
ProShares UltraPro Russell2000
Proporção0.02%
iShares US Small-Cap Equity Factor ETF
Proporção0.02%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
